Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOM-ERA in Rectal Cancer
NCT03904043Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of FOLFOX and Capecitabine + oxaliplatin in rectal adenocarcinoma (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Clinical Complete Response Rate at 22 weeks. Started Jul 2020; status: completed.
02
Drugs
FOLFOXCapecitabine + oxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT03904043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904043.